Long-Term Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study

被引：11
|
作者：
Song, Yuqin
Song, Yongping
Liu, Lihong
Zhang, Mingzhi
Li, Zhiming
Ji, Chunyan
Xu, Wei
Liu, Ting
Xu, Bing
Wang, Xin
Gao, Sujun
Zhang, Huilai
Hu, Yu
Li, Yan
Cheng, Ying
Yang, Haiyan
Cao, Junning
Zhu, Zunmin
Hu, Jianda
Zhang, Wei
Jing, Hongmei
Ding, Kaiyang
Lu, Zhengguang
Zhang, Bin
Zhao, Renbin
Xu, Zhixin
Zhu, Jun
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-141781
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Open-Label Bendamustine Combined with Rituximab for Treatment of Relapsed/Refractory Mantle-Cell Lymphoma: Efficacy and Safety Findings
    Czuczman, Myron S.
    Lamonica, Dominick
    Gaylor, Shari K.
    Bush, Leonard
    Nadolny, Penny
    Colborn, Dave
    BLOOD, 2012, 120 (21)
  • [22] Results of a nonrandomized, open-label, phase II study of combined gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma
    Garbo, Lawrence E.
    Flynn, Patrick J.
    MacRae, Margaret A.
    Rauch, Mary A.
    Wang, Yunfei
    Kolibaba, Kathryn S.
    BLOOD, 2007, 110 (11) : 183B - 183B
  • [23] Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study
    Zhang, Yuchen
    Liu, Panpan
    Cai, Jun
    Jing, Hongmei
    Zou, Liqun
    Huang, Huiqiang
    Wu, Yuanbin
    Li, Wenyu
    Zhong, Liye
    Jin, Xueli
    Ye, Xu
    Feng, Ru
    Zhang, Huilai
    Zhang, Liling
    Lin, Lie
    Sun, Xiuhua
    Tian, Yuyang
    Xia, Zhongjun
    Li, Zhiming
    Huang, He
    Xia, Yi
    Cai, Qingqing
    CANCER MEDICINE, 2022, 11 (22): : 4134 - 4145
  • [24] Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Updated Long Term Results of Phase II Study
    Xu, Wei
    Song, Yongping
    Wang, Tingyu
    Yang, Shenmiao
    Liu, Lihong
    Hu, Yu
    Zhang, Wei
    Zhou, Jianfeng
    Gao, Sujun
    Ding, Kaiyang
    Zhang, Huilai
    Zhu, Zunmin
    Wang, Shunqing
    Xu, Bing
    Hu, Jianda
    Liu, Ting
    Ji, Chunyan
    Xia, Zhongjun
    Li, Yan
    Wang, Xin
    Bin Zhang
    Zhao, Renbin
    Li, Jianyong
    BLOOD, 2021, 138
  • [25] Long-Term Follow-Up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma
    Wang, Michael
    Rule, Simon
    Zinzani, Pier Luigi
    Goy, Andre
    Casasnovas, Oliver
    Smith, Stephen
    Damaj, Gandhi
    Doorduijn, Jeanette K.
    Lamy, Thierry
    Morschhauser, Franck
    Panizo, Carlos
    Shah, Bijal
    Davies, Andrew
    Eek, Richard
    Dupuis, Jehan
    Jacobsen, Eric
    Kater, Arnon P.
    Le Gouill, Steven
    Oberic, Lucie
    Robak, Tadeusz
    Dua, Richa
    Frigault, Melanie M.
    Izumi, Raquel
    Nguyen, Dorothy
    Patel, Priti
    Yin, Ming
    Jurczak, Wojciech
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S316 - S316
  • [26] Long-Term Follow-up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma
    Wang, Michael
    Rule, Simon
    Zinzani, Pier Luigi
    Goy, Andre
    Casasnovas, Olivier
    Smith, Stephen D.
    Damaj, Gandhi
    Doorduijn, Jeanette K.
    Lamy, Thierry
    Morschhauser, Franck
    Panizo, Carlos
    Shah, Bijal D.
    Davies, Andrew
    Eek, Richard
    Dupuis, Jehan
    Jacobsen, Eric
    Kater, Arnon P.
    Gouill, Steven L. E.
    Oberic, Lucie
    Robak, Tadeusz
    Dua, Richa
    Frigault, Melanie M.
    Izumi, Raquel
    Nguyen, Dorothy
    Patel, Priti
    Yin, Ming
    Jurczak, Wojciech
    BLOOD, 2018, 132
  • [27] A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of P276-00, a Cyclin-Dependent Kinase Inhibitor, in Patients With Relapsed or Refractory Mantle Cell Lymphoma
    Cassaday, Ryan D.
    Goy, Andre
    Advani, Suresh
    Chawla, Purvi
    Nachankar, Rajesh
    Gandhi, Mansi
    Gopal, Ajay K.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (07): : 392 - 397
  • [28] Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study
    Noy, Ariela
    de Vos, Sven
    Thieblemont, Catherine
    Martin, Peter
    Flowers, Christopher
    Morschhauser, Franck
    Collins, Graham P.
    Ma, Shuo
    Coleman, Morton
    Peles, Shachar
    Smith, Stephen
    Smith, Alina
    Munneke, Brian
    Dimery, Isaiah
    Beaupre, Darrin
    Chen, Robert W.
    BLOOD, 2016, 128 (22)
  • [29] Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study
    Gopal, Ajay K.
    Schuster, Stephen J.
    Fowler, Nathan H.
    Trotman, Judith
    Hess, Georg
    Hou, Jing-Zhou
    Yacoub, Abdulraheem
    Lill, Michael
    Martin, Peter
    Vitolo, Umberto
    Spencer, Andrew
    Radford, John
    Jurczak, Wojciech
    Morton, James
    Caballero, Dolores
    Deshpande, Sanjay
    Gartenberg, Gary J.
    Wang, Shean-Sheng
    Damle, Rajendra N.
    Schaffer, Michael
    Balasubramanian, Sriram
    Vermeulen, Jessica
    Cheson, Bruce D.
    Salles, Gilles
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (23) : 2405 - +
  • [30] Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study
    Deng, Li-Juan
    Zhou, Ke-Shu
    Liu, Li-Hong
    Zhang, Ming-Zhi
    Li, Zhi-Ming
    Ji, Chun-Yan
    Xu, Wei
    Liu, Ting
    Xu, Bing
    Wang, Xin
    Gao, Su-Jun
    Zhang, Hui-Lai
    Hu, Yu
    Li, Yan
    Cheng, Ying
    Yang, Hai-Yan
    Cao, Jun-Ning
    Zhu, Zun-Min
    Hu, Jian-Da
    Zhang, Wei
    Jing, Hong-Mei
    Ding, Kai-Yang
    Zhang, Xiang-Yang
    Zhao, Ren -Bin
    Zhang, Bin
    Tian, Ya -Min
    Song, Yong-Ping
    Song, Yu-Qin
    Zhu, Jun
    BLOOD ADVANCES, 2023, 7 (16) : 4349 - 4357
12345